An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Tolebrutinib (Primary) ; Colestyramine; Teriflunomide
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
Most Recent Events
- 13 Feb 2026 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2024 Status changed from planning to recruiting.
- 30 Apr 2020 New trial record